Vertex Gets FDA Label Expansion For Alyftrek And Trikafta

01 Apr 2026 //

PHARMIWEB

Vertex Win 2025 Lasker DeBakey Award for Cystic Fibrosis Research

11 Sep 2025 //

PHARMAWEB

CHMP Backs KAFTRIO Label Expansion For Cystic Fibrosis Rare Mutations

28 Feb 2025 //

BUSINESSWIRE

FDA approves Vertex Pharma`s triple combo cystic fibrosis treatment

21 Dec 2024 //

REUTERS

Vertex, beaten by rare disease again, drops 2 assets on growing discard pile

01 Aug 2024 //

FIERCE BIOTECH

As pharma eyes shiny obesity drugs, Vertex tops orphan drug list

24 Apr 2024 //

FIERCE BIOTECH

Ex-Retrophin BD chief flips his rare disease startup onto Nasdaq

24 Sep 2019 //

ENDPTS

FDA fires off a warning on rare cases involving death, adverse liver events

29 Aug 2019 //

ENDPTS

For head of Massachusetts biotech trade group, drug progress is personal

04 Jan 2019 //

STAT NEWS

Vertex to submit Orkambi, Symkevi to SMC

20 Dec 2018 //

PHARMA TIMES

Catalyst will charge $375,000 for rare disease drug

13 Dec 2018 //

STAT NEWS

MPs order release of documents on negotiations for Vertex’ CF drugs

12 Nov 2018 //